EpiDisease wins most disruptive and impactful company award at MIT Entrepreneurship Forum

22/11/2023

The company located in the University of Valencia Science Park (PCUV) has been recognized at the MIT Entrepreneurship Forum Spain in Madrid with the Innovation and Impact Award

EpiDisease, a biomedical company located in the business area of the University of Valencia Science Park (PCUV), was awarded the prize for the most disruptive and impactful company at the MIT Entrepreneurship Forum Spain. The Valencian company, which outperformed 135 competitors from the Life Sciences and Agro sector, was awarded for its disruptive contributions to the improvement of precision medical biomarkers and IVD tools for complex pathologies based on genetic and epigenetic technology platforms. 
 
In recognition of this work, EpiDisease will enjoy a week-long immersion in the Boston biotech ecosystem. This is an experience sponsored by MIT Alumni and the Rafael Pino Foundation, Isabel I University, Basque Culinary Center and VASS. "I am delighted that EpiDisease, has been awarded the MIT Entrepreneurship Forum's award for most disruptive and impactful company. This recognition is a testament to the innovative spirit of our brilliant and dedicated team, whose passion and expertise drive our success, and have made this possible," celebrates José Luis García-Gimenez, co-founder of EpiDisease. 
The MIT Entrepreneurship Forum Spain Innovation and Impact Award consists of a week of immersion in the Boston biotech ecosystem
 
Along these lines, Eva Garcia, COO, adds that EpiDisease has "a mission to revolutionize precision medicine through the development of clinical in vitro diagnostic (IVD) tools." "This award from the MIT Entrepreneurship Forum is a validation of our vision and the applied transformative potential of our work. It reaffirms that we are on the right path, pushing the boundaries, and making a significant impact on the healthcare landscape as a biotech company," she says.
 
James Webb, EpiDisease's director of commercial and institutional relations, stresses the need to "pass on thanks to partners, investors and collaborators who have been instrumental in supporting our journey." "This recognition fuels our determination to continue contributing to the advancement of personalized medicine," he stresses.
 
Calpech and Grupo DUPONTE also received awards along with the company located in the Park as part of the collective celebration of innovation and excellence in the Spanish business panorama.
 

The Park company

EpiDisease S.L. was born in 2014 as a spin off of INCLIVA, of the CIBER of the Instituto de Salud Carlos III and the Universitat de València, with the intention of transferring knowledge in the field of epigenetics and biomedical sciences to the service of society. Along with the development of HISTSHOCK, EpiDisease S.L. is currently developing a portfolio of clinical tools for the diagnosis, prognosis and management of adolescent idiopathic scoliosis that help healthcare professionals to make evidence-based decisions based on individual genetic and epigenetic biomarkers, The CDTI-E.P.E. is a Public Business Entity, under the Ministry of Science and Innovation, which promotes innovation and technological development of Spanish companies. It is the entity that channels applications for aid and support for R&D&I projects of Spanish companies at the national and international level.